NO20034433L - Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil - Google Patents
Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracilInfo
- Publication number
- NO20034433L NO20034433L NO20034433A NO20034433A NO20034433L NO 20034433 L NO20034433 L NO 20034433L NO 20034433 A NO20034433 A NO 20034433A NO 20034433 A NO20034433 A NO 20034433A NO 20034433 L NO20034433 L NO 20034433L
- Authority
- NO
- Norway
- Prior art keywords
- rapamycin
- fluorouracil
- atineoplastic
- gemcitabine
- compositions
- Prior art date
Links
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002949 fluorouracil Drugs 0.000 title abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 2
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- 229960005277 gemcitabine Drugs 0.000 title 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28238801P | 2001-04-06 | 2001-04-06 | |
| US28238501P | 2001-04-06 | 2001-04-06 | |
| PCT/US2002/010912 WO2002080975A1 (en) | 2001-04-06 | 2002-04-05 | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20034433D0 NO20034433D0 (no) | 2003-10-03 |
| NO20034433L true NO20034433L (no) | 2003-11-25 |
Family
ID=26961412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034433A NO20034433L (no) | 2001-04-06 | 2003-10-03 | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1385551B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2004525950A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100862178B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1309421C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE406892T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007242958A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0208627A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2442849A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60228699D1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA010184B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2312568T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0304093A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL157898A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03009092A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20034433L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ540047A (cg-RX-API-DMAC7.html) |
| PL (1) | PL363991A1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1385551E (cg-RX-API-DMAC7.html) |
| SG (1) | SG152906A1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI1385551T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002080975A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX242553B (es) | 2000-10-20 | 2006-12-06 | Eisai Co Ltd | Derivados aromaticos que contienen nitrogeno. |
| CZ309178B6 (cs) | 2001-02-19 | 2022-04-20 | Novartis Pharma Ag | 40-O-(2-hydroxyethyl)rapamycin pro použití při léčení |
| GB0124577D0 (en) * | 2001-10-12 | 2001-12-05 | Novartis Forschungsstiftung | Novel methods |
| EP1478648B1 (en) | 2002-02-01 | 2014-04-30 | ARIAD Pharmaceuticals, Inc. | Phosphorus-containing compounds and uses thereof |
| UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
| EP1683785B1 (en) | 2003-11-11 | 2013-10-16 | Eisai R&D Management Co., Ltd. | Urea derivative and process for producing the same |
| AU2005216898A1 (en) * | 2004-02-26 | 2005-09-09 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
| WO2006027545A2 (en) * | 2004-09-10 | 2006-03-16 | Agency For Science, Technology And Research | Method |
| CA2579810C (en) | 2004-09-17 | 2012-01-24 | Eisai R&D Management Co., Ltd. | Stable pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide |
| DE602006021142D1 (de) | 2005-02-03 | 2011-05-19 | Gen Hospital Corp | Verfahren zur behandlung von gefitinib-resistentem krebs |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| PE20070763A1 (es) * | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| EP2662082A1 (en) * | 2005-11-14 | 2013-11-13 | Ariad Pharmaceuticals, Incorporated | Administration of mTOR inhibitors |
| GB0523658D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| CA2629245C (en) * | 2005-11-21 | 2016-07-12 | Novartis Ag | Neuroendocrine tumor treatment |
| BRPI0706528A2 (pt) * | 2006-01-12 | 2011-03-29 | Novartis Ag | combinação de inibidor de mtor e composto antifolato |
| EP1880723A1 (en) * | 2006-07-14 | 2008-01-23 | Novartis AG | Combination of mTOR inhibitor and antifolate compound |
| JP5372737B2 (ja) | 2006-03-13 | 2013-12-18 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療 |
| EP2004163B1 (en) * | 2006-04-05 | 2014-09-17 | Novartis Pharma AG | Combination of everolimus and vinorelbine |
| AU2007252506C1 (en) | 2006-05-18 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| US20090311249A1 (en) * | 2006-06-02 | 2009-12-17 | Luca Gianni | Capecitabine Combination Therapy |
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| EP2087113A2 (en) * | 2006-10-11 | 2009-08-12 | Fusion Antibodies Limited | Combination therapy |
| US20080161335A1 (en) | 2006-11-14 | 2008-07-03 | Vladyka Ronald S | Oral formulations |
| CN101616671A (zh) | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| RU2483714C2 (ru) * | 2007-03-07 | 2013-06-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. | Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента |
| PT2155188E (pt) | 2007-06-01 | 2013-12-19 | Abraxis Bioscience Llc | Métodos e composições para o tratamento de cancro recorrente |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| AU2009225434B2 (en) | 2008-03-21 | 2014-05-22 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| CN109464445A (zh) | 2008-08-04 | 2019-03-15 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| LT3000467T (lt) | 2009-04-06 | 2023-04-11 | Wyeth Llc | Krūties vėžio gydymo schema naudojant neratinibą |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| EP2937337A4 (en) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 抗がん剤 |
| EP3338779B1 (en) | 2015-08-20 | 2021-06-30 | Eisai R&D Management Co., Ltd. | Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor |
| KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| IL273579B2 (en) | 2017-09-27 | 2025-10-01 | Incyte Corp | Salts of pyrrolizidine derivatives used as Tm inhibitors. |
| HRP20250676T1 (hr) | 2018-06-29 | 2025-08-01 | Incyte Corporation | Formulacije inhibitora axl/mer |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
| BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| NZ336676A (en) * | 1997-01-24 | 2000-01-28 | Norsk Hydro As | Gemcitabine esters or amides useful as anti-cancer and anti-viral agents |
| TW466112B (en) * | 1998-04-14 | 2001-12-01 | Lilly Co Eli | Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same |
-
2002
- 2002-04-05 DE DE60228699T patent/DE60228699D1/de not_active Expired - Fee Related
- 2002-04-05 SI SI200230737T patent/SI1385551T1/sl unknown
- 2002-04-05 IL IL15789802A patent/IL157898A0/xx unknown
- 2002-04-05 NZ NZ540047A patent/NZ540047A/en unknown
- 2002-04-05 PL PL02363991A patent/PL363991A1/xx unknown
- 2002-04-05 BR BR0208627-1A patent/BR0208627A/pt not_active IP Right Cessation
- 2002-04-05 WO PCT/US2002/010912 patent/WO2002080975A1/en not_active Ceased
- 2002-04-05 MX MXPA03009092A patent/MXPA03009092A/es active IP Right Grant
- 2002-04-05 SG SG200506382-1A patent/SG152906A1/en unknown
- 2002-04-05 EP EP02726710A patent/EP1385551B1/en not_active Expired - Lifetime
- 2002-04-05 ES ES02726710T patent/ES2312568T3/es not_active Expired - Lifetime
- 2002-04-05 CN CNB028077490A patent/CN1309421C/zh not_active Expired - Fee Related
- 2002-04-05 JP JP2002579013A patent/JP2004525950A/ja active Pending
- 2002-04-05 EA EA200301091A patent/EA010184B1/ru not_active IP Right Cessation
- 2002-04-05 PT PT02726710T patent/PT1385551E/pt unknown
- 2002-04-05 AT AT02726710T patent/ATE406892T1/de not_active IP Right Cessation
- 2002-04-05 KR KR1020037013090A patent/KR100862178B1/ko not_active Expired - Fee Related
- 2002-04-05 CA CA002442849A patent/CA2442849A1/en not_active Withdrawn
- 2002-04-05 HU HU0304093A patent/HUP0304093A3/hu unknown
-
2003
- 2003-10-03 NO NO20034433A patent/NO20034433L/no not_active Application Discontinuation
-
2007
- 2007-12-13 AU AU2007242958A patent/AU2007242958A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE60228699D1 (de) | 2008-10-16 |
| ATE406892T1 (de) | 2008-09-15 |
| CN1545419A (zh) | 2004-11-10 |
| NO20034433D0 (no) | 2003-10-03 |
| KR100862178B1 (ko) | 2008-10-09 |
| EP1385551B1 (en) | 2008-09-03 |
| ES2312568T3 (es) | 2009-03-01 |
| EA010184B1 (ru) | 2008-06-30 |
| CN1309421C (zh) | 2007-04-11 |
| CA2442849A1 (en) | 2002-10-17 |
| HK1060062A1 (en) | 2004-07-30 |
| BR0208627A (pt) | 2004-03-09 |
| SG152906A1 (en) | 2009-06-29 |
| PT1385551E (pt) | 2008-11-03 |
| WO2002080975A1 (en) | 2002-10-17 |
| HUP0304093A2 (hu) | 2004-04-28 |
| IL157898A0 (en) | 2004-03-28 |
| JP2004525950A (ja) | 2004-08-26 |
| PL363991A1 (en) | 2004-11-29 |
| HUP0304093A3 (en) | 2008-08-28 |
| AU2007242958A1 (en) | 2008-01-10 |
| KR20040007491A (ko) | 2004-01-24 |
| EA200301091A1 (ru) | 2004-02-26 |
| NZ540047A (en) | 2007-01-26 |
| MXPA03009092A (es) | 2004-02-12 |
| EP1385551A1 (en) | 2004-02-04 |
| SI1385551T1 (sl) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034433D0 (no) | Atineoplastiske blandinger slik som rapamycin sammen med gemcitabin eller fluorouracil | |
| ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
| NO20034094L (no) | Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat | |
| ECSP056001A (es) | Combinaciones antineoplásicas | |
| BR0211769A (pt) | Combinações antineoplásicas | |
| NO20032181D0 (no) | Anvendelse av CCI-779 som et antineoplastisk middel | |
| AR028512A1 (es) | Composiciones antimicrobianas acidas para el tratamiento de alimentos y superficies que contactan alimentos y metodos para la utilizacion de estas | |
| BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| NO20041998L (no) | Benzoksazin og benzotiazinderivater og farmasoytiske sammensetninger som inneholder dem | |
| NO20042288L (no) | Kinazolinderivater som antitumormidler | |
| CY1111613T1 (el) | Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv | |
| NO20025150L (no) | 2-acylindolderivater og deres anvendelse som antitumormidler | |
| IL162726A0 (en) | Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | |
| EP1476419A4 (en) | N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE | |
| NO20040175L (no) | Acylsemikarbazider som cyklinavhengige kineaseinhibitorer anvendelige som anti-kreft- og anti-proliferative midler | |
| BR0210101A (pt) | Combinações antineoplásticas | |
| ECSP034813A (es) | Arilsulfonamidas como agentes antivirales | |
| ECSP034790A (es) | Combinaciones antineoplásticas tales como rapamicin junto con gemcitabina o fluorouracil | |
| BR0208566B1 (pt) | Derivados de Beta-Carbolina, Seu Uso, e composição Farmacêutica | |
| ITVR20010031A0 (it) | Uso di epigallocatechin-3-gallato o suoi derivati nella profilassi e nel trattamento delle malattie neurodegenerative. | |
| NO20061402L (no) | Anti-tumorformuleringer som omfatter defibrotid alene eller i kombinasjon med andre antitumormidler | |
| BR0309923B1 (pt) | Formulação aquosa de poliuretano, e, uso da mesma | |
| DK1799696T3 (da) | Phosphoindoler som HIV-inhibitorer | |
| DK1545553T3 (da) | Anvendelse af alkylphosphocholiner i kombination med antitumormedikamenter | |
| FI20040531A7 (fi) | Insuliiniresistenttien tilojen hoitaminen ja diagnosointi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |